title: Compromised local control due to treatment interruptions and late treatment breaks in early glottic cancer: Population-based outcomes study supporting need for intensified treatment schedules.
abstract: OBJECTIVE
  This population-based study describes the treatment of early glottic cancer in Ontario, Canada and assesses whether treatment variations were associated with treatment effectiveness.
  
  
  METHODS
  We studied 491 T1N0 and 213 T2N0 patients. Data abstracted from charts included age, sex, stage, treatment details, disease control, and survival.
  
  
  RESULTS
  The total dose ranged from 50 to 70 Gy, and the daily dose ranged from 1.9 to 2.8 Gy. In 90%, treatment duration was between 25 and 50 days. Field sizes, field reductions, beam arrangement, and beam energy varied. Late treatment breaks occurred in 13.6% of T1N0 and 27.1% of T2N0 cases. Local control was comparable to other reports for T1N0 (82% at 5 years), but was only 63.2% in T2N0. Variables associated with local failure in T1N0 were age less than 49 years (relative risk [RR], 3.21; 95% confidence interval [CI], 1.49-6.90) and >3 treatment interruption days (RR, 2.43; 95% CI, 1.00-5.91). In T2N0, these were field reduction (RR, 2.33; 95% CI, 1.23-4.42) and late treatment breaks (RR, 2.19; 95% CI, 1.09-4.41).
  
  
  CONCLUSIONS
  Some aspects of treatment for early glottic cancer were associated with worse local control. Problems with protracted treatment are of particular concern, underscoring the need for randomized studies to intensify radiotherapy.
authors.affiliation: Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada. patti.groome@krcc.on.ca
authors.forename: Patti A
authors.initials: PA
authors.lastname: Groome
authors.forename: Brian
authors.initials: B
authors.lastname: O'Sullivan
authors.forename: William J
authors.initials: WJ
authors.lastname: Mackillop
authors.forename: Lynda D
authors.initials: LD
authors.lastname: Jackson
authors.forename: Karleen
authors.initials: K
authors.lastname: Schulze
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Irish
authors.forename: Padraig R
authors.initials: PR
authors.lastname: Warde
authors.forename: Ken M
authors.initials: KM
authors.lastname: Schneider
authors.forename: Robert G
authors.initials: RG
authors.lastname: Mackenzie
authors.forename: D Ian
authors.initials: DI
authors.lastname: Hodson
authors.forename: J Alex
authors.initials: JA
authors.lastname: Hammond
authors.forename: Sunil P P
authors.initials: SP
authors.lastname: Gulavita
authors.forename: Libni J
authors.initials: LJ
authors.lastname: Eapen
authors.forename: Peter F
authors.initials: PF
authors.lastname: Dixon
authors.forename: Randy J
authors.initials: RJ
authors.lastname: Bissett
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy*; D016001:Confidence Intervals; D019583:Dose Fractionation, Radiation; D005931:Glottis; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D008875:Middle Aged; D009367:Neoplasm Staging; D009864:Ontario; D012044:Regression Analysis; D012189:Retrospective Studies; D016896:Treatment Outcome